Julius L. Chambers Biomedical/Biotechnology Institute and Department of Biological & Biomedical Sciences, North Carolina Central University, Durham, NC 27707, USA.
Int J Mol Sci. 2020 Jun 23;21(12):4449. doi: 10.3390/ijms21124449.
The consequences of prostate cancer metastasis remain severe, with huge impact on the mortality and overall quality of life of affected patients. Despite the convoluted interplay and cross talk between various cell types and secreted factors in the metastatic process, cytokine and chemokines, along with their receptors and signaling axis, constitute important factors that help drive the sequence of events that lead to metastasis of prostate cancer. These proteins are involved in extracellular matrix remodeling, epithelial-mesenchymal-transition, angiogenesis, tumor invasion, premetastatic niche creation, extravasation, re-establishment of tumor cells in secondary organs as well as the remodeling of the metastatic tumor microenvironment. This review presents an overview of the main cytokines/chemokines, including IL-6, CXCL12, TGFβ, CXCL8, VEGF, RANKL, CCL2, CX3CL1, IL-1, IL-7, CXCL1, and CXCL16, that exert modulatory roles in prostate cancer metastasis. We also provide extensive description of their aberrant expression patterns in both advanced disease states and metastatic sites, as well as their functional involvement in the various stages of the prostate cancer metastatic process.
前列腺癌转移的后果仍然严重,对受影响患者的死亡率和整体生活质量产生巨大影响。尽管在转移过程中各种细胞类型和分泌因子之间存在复杂的相互作用和串扰,但细胞因子和趋化因子及其受体和信号轴仍然是重要的因素,有助于驱动导致前列腺癌转移的一系列事件。这些蛋白参与细胞外基质重塑、上皮-间充质转化、血管生成、肿瘤侵袭、前转移龛形成、外渗、肿瘤细胞在次级器官中的重新建立以及转移瘤微环境的重塑。这篇综述概述了主要的细胞因子/趋化因子,包括 IL-6、CXCL12、TGFβ、CXCL8、VEGF、RANKL、CCL2、CX3CL1、IL-1、IL-7、CXCL1 和 CXCL16,它们在前列腺癌转移中发挥调节作用。我们还广泛描述了它们在晚期疾病状态和转移部位的异常表达模式,以及它们在前列腺癌转移过程的各个阶段中的功能参与。
Int J Mol Sci. 2020-6-23
Semin Cancer Biol. 2022-11
Oncogene. 2013-7-15
Cancer Metastasis Rev. 2021-6
J Transl Med. 2025-6-3
Biology (Basel). 2025-5-6
Naunyn Schmiedebergs Arch Pharmacol. 2025-4-14
Cancers (Basel). 2025-3-20
Cancer Manag Res. 2025-2-1
Int J Mol Sci. 2024-12-23
Cancers (Basel). 2024-12-11
Oncology. 2024-10-9
Signal Transduct Target Ther. 2020-3-12
Medicines (Basel). 2019-7-30
Acta Clin Croat. 2019-3
Carcinogenesis. 2019-12-31
Int J Mol Sci. 2019-6-5